Navigation Links
Garner to Lead Virginia Bioinformatics Institute
Date:10/16/2009

BLACKSBURG, Va., Oct. 16 /PRNewswire-USNewswire/ -- Harold "Skip" Garner has been named executive director of the Virginia Bioinformatics Institute (VBI) at Virginia Tech. Garner joins VBI from the University of Texas Southwestern Medical Center (UTSW), where he was professor of Biochemistry and Internal Medicine and the Philip O'Bryan Montgomery Jr., M.D. Distinguished Chair in Developmental Biology. Before coming to UTSW in 1994, Garner served as a senior staff scientist and founder of the Bioscience Division at General Atomics in San Diego.

"We are delighted to have someone of the caliber of Dr. Garner accept the challenge of leading VBI into its next phase of development," said Virginia Tech University Distinguished Professor Paul Knox, who chaired the search committee for the executive director position. "Dr. Garner impressed everyone with his enthusiasm and knowledge for VBI and has a clear vision of how to build upon the success of this internationally competitive research institute."

"I welcome Dr. Garner to VBI and Virginia Tech," said Virginia Tech President Charles W. Steger. "He brings an impressive array of skills and experiences to the university at an exciting point in the growth of our research programs. I know he looks forward to the opportunities to build on VBI's scientific achievements, to strengthen collaborations with our colleges, to foster innovation throughout our campus, including in undergraduate research, and to embrace the research and education possibilities offered by the new Virginia Tech Carilion School of Medicine and Research Institute." Steger added, "Dr. Garner's expertise and fit with Virginia Tech's many innovative scientific programs will be a key asset moving forward."

Researchers at VBI are engaged in a wide range of scientific projects that span bioinformatics and systems biology to high-performance computing, complexity science, and policy and decision informatics. Garner remarked, "VBI has an excellent track record of exploring the interface of biology, medicine and the physical sciences. The institute is in an ideal position to take advantage of the many exciting opportunities that are materializing in fields such as genetics, computational biology, and clinical research." He added: "VBI will continue to build on its strengths as one of the leading international institutes for informatics and infectious disease research."

Garner's current research focuses on three areas: applied computational biology; advanced instrumentation development; and genetics, genomics, and proteomics research that builds upon software findings and instrumentation capabilities. This includes research projects that focus on text mining (deriving high-quality information from text) and DNA microsatellite analysis (the study of short, repetitive DNA sequences that may have clinical applications).

Garner added: "Opportunities in the life sciences are opening up across the Virginia Tech campus, including possibilities to partner with translational science initiatives at the recently created Virginia Tech Carilion School of Medicine and Research Institute. VBI will work closely with Virginia Tech and key partners as part of its mission to drive science, facilitate policy and decision-making, and produce meaningful outcomes for society. We will also be moving ahead with our business development efforts to make VBI's research achievements more available via commercialization."

Garner received his Ph.D. in Plasma Physics from the University of Wisconsin-Madison in 1982. He has published widely in leading peer-reviewed journals throughout his career in plasma physics and bioengineering. He sits on several corporate advisory boards and advises government and private agencies. Garner is the founder of several biotechnology companies, including Heliotext, Xanapath, BioAutomation, and Light Biology, which was acquired by Nimblegen (now Roche Nimblegen Inc.), in 2004.

About the Virginia Bioinformatics Institute

The Virginia Bioinformatics Institute (VBI) at Virginia Tech has a research platform centered on understanding the "disease triangle" of host-pathogen-environment interactions in plants, humans and other animals. By successfully channeling innovation into transdisciplinary approaches that combine information technology and biology, researchers at VBI are addressing some of today's key challenges in the biomedical, environmental and plant sciences. https://www.vbi.vt.edu/

About Virginia Tech

Founded in 1872 as a land-grant college, Virginia Tech (http://www.vt.edu/) is the most comprehensive university in the Commonwealth of Virginia and is among the top research universities in the nation. Today, Virginia Tech's nine colleges are dedicated to quality, innovation, and results through teaching, research, and outreach activities. At its 2,600-acre main campus located in Blacksburg and other campus centers in Northern Virginia, Southwest Virginia, Hampton Roads, Richmond, Southside, and Roanoke, Virginia Tech enrolls more than 28,000 undergraduate and graduate students from all 50 states and more than 100 countries in 180 academic degree programs.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.

SOURCE Virginia Tech


'/>"/>
SOURCE Virginia Tech
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Biotech Labs(R) Garners 2009 Utah Best of State Award
2. Three Firms, Two Training Programs Garner Greater Baltimore Committees 2009 Bioscience Awards
3. New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine
4. Virginia Now Owns Three Top National Business Rankings
5. Virginia Tech engineers investigate energy independent monitoring system for bridges
6. Virginia Tech researchers discover how mosquitoes avoid succumbing to viruses they transmit
7. Huntington Area Development Council Attracts Technology-Based Startup Companies With $150,000 Grant From Verizon West Virginia
8. Virginia Tech engineers identify conditions that initiate erosion
9. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
10. A Communitys Fight to Preserve its Historical and Rural Culture in Virginia: Biotechnology CEO Gets Involved
11. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
Breaking Biology News(10 mins):